Wound Care Stocks Are Posting Double-Digit Growth. Here’s Why.
Key Highlights
- ➤Lilly (LLY) Q2 revenue $23.0B, up 48%; raises 2026 guidance to $85.0B-$87.0B
- ➤Solventum (SOLV) Q2 sales $2.2B; raises 2026 organic growth and EPS guidance
- ➤Vericel (VCEL) Q2 revenue $77.5M, up 22%; raises 2026 revenue guidance to $330M-$340M
- ➤Axogen (AXGN) Q2 revenue $69.7M, up 23.1%; raises 2026 revenue guidance to at least $279M
- ➤Conexeu (CNXU) scaled CXU batches met specifications; targets first-quarter 2027 FDA 510(k) submission
Expert Statements
Miles Harrison, President and CEO of Conexeu Sciences
“We have moved from process development to implementing a controlled manufacturing process”
Miles Harrison, President and CEO of Conexeu Sciences
“That progress is important for two reasons. First, it supports the regulatory testing required to advance our planned FDA 510(k) submission. Second, it moves us closer to establishing the scalable manufacturing infrastructure needed to support commercialization. We believe manufacturing scale-up is one of the critical bridges between regulatory development and our ability to ultimately bring our lead device to market.”
Brian Pilcher, Ph.D., Chief Medical Officer of Conexeu Sciences
“Wherever appropriate, we are running these workstreams at the same time rather than one after another, using representative test materials made with our controlled manufacturing process.”
Brian Pilcher, Ph.D., Chief Medical Officer of Conexeu Sciences
“This approach keeps our planned first-quarter 2027 submission on track while maintaining the consistency that regulatory testing requires.”
Nick Colangelo, CEO of Vericel Corporation
“The Company delivered excellent financial and business results in the second quarter as we continue to generate top-tier revenue and profit growth as well as significant free cash flow”
Michael Dale, President and CEO of Axogen
“We are pleased with our second-quarter revenue performance and the progress we’re making across each of Axogen’s strategic plan priorities”
David A. Ricks, Chair and CEO of Eli Lilly and Company
“Lilly’s momentum continues, as we delivered 48% revenue growth and raised our full-year guidance. At the same time, Lilly is building for the future.”
RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - The global advanced wound care market is valued at $13.37 billion in 2025 and is projected to reach $19.32 billion by 2030, a compound annual growth rate of 7.6%, according to MarketsandMarkets. The firm points to chronic disease, an aging population and traumatic injuries as the main drivers, noting that diabetic foot ulcers affect roughly a quarter of patients with diabetes and are a leading cause of hospitalization. Active Companies from around the markets with current developments this week include: Conexeu Sciences Inc. (Nasdaq: CNXU), Solventum Corporation (NYSE: SOLV), Vericel Corporation (Nasdaq: VCEL), Axogen, Inc. (Nasdaq: AXGN), Eli Lilly and Company (NYSE: LLY).
North America holds the largest share of that market today, according to the same report, which also credits strengthened reimbursement frameworks with supporting broader adoption of advanced therapies. The category spans negative pressure wound therapy, advanced dressings, skin substitutes and biologic matrices, and the large players in it are reporting steady growth.
Get started
Create a free account to read the full story.